Skip to main content
. 2022 Jul 20;108(2):123–130. doi: 10.1136/archdischild-2022-324375

Figure 2.

Figure 2

SARS-CoV-2 seroprevalence (RocheS (anti-SARS-CoV-2 IgG spike protein antibodies) and RocheN (anti-SARS-CoV-2 IgG nucleocapsid antibodies)) by age group and time period October 2019–June 2021 in England, adjusted for National Health Service region and ethnicity. Error bars indicate 95% CI.